+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
MALE
ID06931340

Evaluating Docetaxel Addition to Hormonal Therapy and Apalutamide in Treating Metastatic Castrate-Sensitive Prostate Cancer

Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-03

1260

Participants Needed

214

Research Sites

390 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether adding docetaxel chemotherapy to the usual treatment of hormonal therapy and apalutamide improves outcomes for men with metastatic prostate cancer that has spread from the original site to other parts of the body. This phase III trial aims to determine if this combination improves overall survival and delays disease progression. The study also investigates effects on symptoms, quality of life, and safety, considering genetic factors and disease volume. Participants are randomly assigned to one of two groups. One group receives androgen deprivation therapy ADT and apalutamide orally once daily, with treatment cycles repeated every 12 weeks if tolerated and without disease progression. The other group receives the same hormonal treatments plus docetaxel chemotherapy given intravenously every 21 days for up to six doses. Throughout the study, patients undergo CT or MRI scans and bone scans, with optional PSMA-PET scans and blood sample collections. During the trial, participants are regularly monitored with imaging tests and questionnaires to assess disease status, symptoms, and quality of life. The main outcome measured is overall survival, tracked for up to 10 years after randomization. Secondary outcomes include time to disease progression, skeletal events, prostate-specific antigen changes, and treatment safety. After completing treatment, participants have follow-up visits every six months for up to ten years to track long-term effects and survival.

CONDITIONS

Brief Title

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Research Team

S

Shiva Baghaie, MPH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here